Residency · Residency · Family Medicine
Insomnia: Cognitive Behavioral Therapy and Beyond
Introduction
Chronic insomnia affects approximately 10 to 15% of adults and is associated with impaired daytime functioning, increased healthcare utilization, and elevated risk of depression, cardiovascular disease, and accidents. Family physicians are the primary point of contact for most insomnia complaints. Evidence strongly supports cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment, ahead of pharmacotherapy.
Definitions and Diagnostic Criteria
Chronic insomnia disorder, per ICSD-3 and DSM-5, is defined as difficulty initiating or maintaining sleep, or early morning awakening, occurring at least three nights per week for at least three months, despite adequate sleep opportunity, causing clinically significant distress or functional impairment. Short-term insomnia consists of symptoms lasting less than three months, often triggered by an identifiable stressor. It is important to distinguish insomnia from sleep deprivation (insufficient sleep opportunity) and from other sleep disorders such as obstructive sleep apnea and restless legs syndrome.
Assessment
Clinical History
The complaint should be characterized as sleep-onset insomnia, sleep-maintenance insomnia, or early morning awakening. The sleep-wake schedule, napping patterns, and daytime functioning should be assessed. Comorbid conditions should be screened for, including depression (PHQ-9), anxiety (GAD-7), chronic pain, GERD, and nocturia. The medication list should be reviewed for sleep-disrupting agents such as stimulants, beta-blockers, corticosteroids, SSRIs, and diuretics. Caffeine, alcohol, and substance use should be assessed, along with shift work and circadian rhythm disruption.
Sleep Diary
A two-week prospective sleep diary is the cornerstone of assessment. It records bedtime, estimated sleep onset, nocturnal awakenings, wake time, time out of bed, and perceived sleep quality. Sleep efficiency is calculated as total sleep time divided by time in bed, multiplied by 100; normal is greater than 85%.
Validated Questionnaires
The Insomnia Severity Index (ISI) is a seven-item tool with scores of 8 to 14 indicating subthreshold insomnia, 15 to 21 moderate, and 22 to 28 severe. The STOP-BANG should be used to screen for obstructive sleep apnea if snoring, witnessed apneas, or excessive daytime sleepiness are present. The Epworth Sleepiness Scale differentiates sleepiness (suggestive of sleep apnea or narcolepsy) from fatigue.
When to Order Sleep Studies
Polysomnography is not indicated for routine insomnia evaluation. It should be ordered when there is clinical suspicion for obstructive sleep apnea, periodic limb movement disorder, or narcolepsy.
Cognitive Behavioral Therapy for Insomnia (CBT-I)
CBT-I is the first-line treatment for chronic insomnia per the American Academy of Sleep Medicine, the American College of Physicians, and the European Sleep Research Society.
Components of CBT-I
Sleep Restriction Therapy
Time in bed is limited to match actual total sleep time, with a minimum of five hours. This consolidates sleep drive and increases sleep efficiency. Time in bed is gradually extended by 15 to 30 minutes per week as sleep efficiency exceeds 85%. Temporary increased daytime sleepiness during initial restriction is expected, and patients should be counseled about driving safety.
Stimulus Control
Patients should go to bed only when sleepy and use the bed only for sleep and sexual activity. If unable to fall asleep within 15 to 20 minutes, they should get up and engage in a quiet, non-stimulating activity in dim light. A consistent wake time should be maintained regardless of sleep quality, and napping should be avoided.
Cognitive Restructuring
Maladaptive beliefs about sleep, such as "I must get eight hours or I cannot function," should be identified and challenged. Catastrophic thinking about the consequences of poor sleep should be addressed. Realistic expectations about normal sleep variability should be reframed.
Sleep Hygiene Education
A consistent sleep-wake schedule should be maintained seven days a week. The sleep environment should be cool, dark, and quiet. Screens (blue light) should be avoided for 30 to 60 minutes before bed. Caffeine should be limited after noon, and alcohol should be avoided within three hours of bedtime. Regular exercise is beneficial but should not occur within two to three hours of bedtime.
Relaxation Techniques
Progressive muscle relaxation, diaphragmatic breathing, and guided imagery and mindfulness meditation are all useful techniques.
Delivery of CBT-I
Traditional CBT-I involves four to eight sessions with a trained therapist. Digital CBT-I through apps (Insomnia Coach, CBT-I Coach) and online programs has demonstrated efficacy comparable to in-person delivery. Brief behavioral treatment for insomnia (BBTI) is a condensed version deliverable by primary care clinicians in one to two sessions.
Pharmacotherapy
General Principles
Pharmacotherapy is second-line and should be used when CBT-I is unavailable, ineffective, or as a short-term adjunct. The lowest effective dose should be used for the shortest duration, and the need for continued pharmacotherapy should be reassessed at regular intervals.
Medication Options
| Drug Class | Examples | Best For | Key Concerns |
|---|---|---|---|
| Melatonin receptor agonists | Ramelteon 8 mg | Sleep-onset insomnia | No abuse potential |
| DORAs | Suvorexant 10-20 mg, lemborexant 5-10 mg | Onset + maintenance | Next-day somnolence |
| Low-dose antidepressants | Trazodone 25-100 mg, doxepin 3-6 mg | Maintenance; comorbid depression | Orthostatic hypotension (trazodone) |
| Z-drugs | Zolpidem, eszopiclone | Short-term use only (2-4 wks) | Tolerance, dependence, parasomnias; avoid in elderly |
| Avoid | Benzodiazepines, diphenhydramine | — | Cognitive impairment, falls, dependence |
Melatonin Receptor Agonists
Ramelteon (8 mg at bedtime) targets MT1/MT2 receptors, has no abuse potential, and is best for sleep-onset insomnia. Melatonin (0.5 to 5 mg) is available over the counter with modest evidence and may help with circadian misalignment.
Dual Orexin Receptor Antagonists (DORAs)
Suvorexant (10 to 20 mg) and lemborexant (5 to 10 mg) block wake-promoting orexin signaling. They are effective for both sleep onset and sleep maintenance, are generally well tolerated, and should be monitored for next-day somnolence.
Low-Dose Sedating Antidepressants
Trazodone (25 to 100 mg) is widely prescribed off-label but has limited long-term efficacy data and carries risk of orthostatic hypotension and priapism. Doxepin (3 to 6 mg) is FDA-approved for sleep-maintenance insomnia and has minimal anticholinergic effects at low doses.
Benzodiazepine Receptor Agonists (Z-drugs)
Zolpidem, zaleplon, and eszopiclone are effective short-term but associated with tolerance, dependence, parasomnias, and next-day impairment. They should be avoided in older adults (Beers Criteria), and if prescribed, should be used for the shortest duration possible (two to four weeks).
Agents to Avoid
Benzodiazepines are not recommended for chronic insomnia due to tolerance, dependence, cognitive impairment, and fall risk. Diphenhydramine and doxylamine carry anticholinergic burden, cause cognitive impairment and next-day sedation, and should be avoided in older adults. Gabapentin and quetiapine are frequently prescribed off-label but lack strong insomnia-specific evidence and carry significant side effect burden.
Special Populations
In older adults, CBT-I is particularly effective and preferred. Anticholinergic and benzodiazepine agents should be avoided, with low-dose doxepin or ramelteon being safer pharmacologic options. In pregnancy, CBT-I is first-line, as most sleep medications lack adequate safety data. In patients with comorbid depression, both conditions should be treated, and CBT-I improves depression outcomes independently. In patients with chronic pain, CBT-I is effective and can reduce pain perception; medications with abuse potential should be avoided.
Clinical Pearls
CBT-I has durable effects that persist long after treatment ends, unlike pharmacotherapy where insomnia typically recurs upon discontinuation. Sleep restriction is the most potent component of CBT-I but requires careful counseling about temporary sleepiness. Sleep hygiene alone is insufficient to treat chronic insomnia and must be combined with behavioral interventions. Every insomnia patient should be screened for depression, anxiety, and obstructive sleep apnea before initiating treatment. Digital CBT-I programs are evidence-based, widely accessible, and can bridge the gap when trained therapists are unavailable.
References
- Qaseem A, Kansagara D, Forciea MA, et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-133.
- Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(2):255-262.
- Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675-700.
- Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract. 2012;13:40.